---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088247"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:28:56.019228+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics appoints Lucy To as CFO effective August 12, 2024

## Summary
- Lucy To appointed CFO; Mark Conley reassumes VP Finance role effective August 12.
- To brings 18+ years experience; most recently MD at Wells Fargo Healthcare IB.
- Employment agreement: $475K base, $125K signing bonus, 125K stock options vesting over 4 years.
- Top-line Phase 1 data for T1D drug SAB-142 expected by end of 2024 per press release.

## SEC filing metadata
- accession: 0000950170-24-088247
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/sabs-20240726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088247
- JSON: https://secwatch.observer/filing/0000950170-24-088247.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088247.txt

## Key facts
- Executive change
  Lucy To was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm
- Executive change
  Mark Conley changed role as Vice President of Finance at SAB Biotherapeutics, Inc..
  - Action: reassume
  - Role: Vice President of Finance
  source text: Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.